Given the high energy demands of CSCs, VDAC1 is often overexpressed in various cancers, including glioblastoma, cervical, and lung cancers, where it facilitates tumor progression and therapy resistance [54, 94]. This evidence concerns the gene VDAC1 and lung carcinoma.